#United States #New York #Class Action #Pomerantz LLP #Immutep Limited

Significant Legal Action Against Immutep Limited

In a noteworthy development for shareholders of Immutep Limited, Pomerantz LLP has initiated a class action lawsuit against the company, represented by the ticker symbol IMMP on NASDAQ. This legal battle centers on allegations that Immutep and certain of its executives may have engaged in practices related to securities fraud, raising significant concerns for investors who have suffered losses.

Understanding the Class Action

The lawsuit invites stakeholders who believe they have incurred losses on their investments in Immutep to come forward. Interested parties are encouraged to reach out to Danielle Peyton at Pomerantz via email or phone. It’s essential for those contacting the firm to provide their mailing address, phone number, and details about their shares purchased.

The action pertains to whether Immutep’s management failed to disclose crucial information leading to an unfair trading environment and whether their conduct could be deemed as fraudulent.

Recent Developments

A critical piece of information arose on March 13, 2026, when Immutep issued a press release. The Independent Data Monitoring Committee (IDMC) for their TACTI-004 Phase III clinical trial, which evaluated the drug eftilagimod alfa for the treatment of non-small cell lung cancer, recommended halting the trial due to lack of efficacy. This announcement significantly impacted Immutep's stock, resulting in a staggering 82.44% drop, closing at just $0.48 per American Depositary Receipt (ADR). Investors are understandably alarmed about the implications of this announcement, prompting the need for a legal examination of the company’s practices.

This abrupt change has raised questions about the company's transparency and the decision-making process of its executives, all of which will be central to the class action lawsuit. Stakeholders are advised to consider their options carefully as the landscape unfolds.

Key Dates

Investors looking to be part of the class action have until July 6, 2026, to apply for the position of Lead Plaintiff in the case. This status is crucial as it gives individuals a central role in spearheading the legal proceedings on behalf of the entire class of affected investors. Detailed information regarding the complaint can be found on Pomerantz’s official website.

About Pomerantz LLP

Founded by Abraham L. Pomerantz, a prominent figure in class action litigation, Pomerantz LLP holds a distinguished reputation as a leading firm in securities class actions. With over 85 years of experience, the firm continues its mission to advocate for victims of securities fraud and corporate misconduct. Notably, Pomerantz has successfully secured multi-million dollar settlements for investors, reflecting its commitment to holding companies accountable for their actions.

In conclusion, the legal action against Immutep Limited is an important development for investors, presenting a chance to address grievances stemming from potential securities fraud. As updates continue to emerge, shareholders should remain vigilant and consider their involvement in this class action for the opportunity to seek redress for their losses.